Antares Pharma (NASDAQ:ATRS) Raised to Hold at Zacks Investment Research


Share on StockTwits

Antares Pharma (NASDAQ:ATRS) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Tuesday, Zacks.com reports.

According to Zacks, “Antares Pharma, Inc. develops, commercializes and markets novel delivery solutions, including needle-free and mini-needle injector systems, gel technologies and transdermal products, which improve both the efficiency of drug therapies and the quality of life for patients. The Company currently distributes its needle-free injector systems for the delivery of insulin and growth hormone in over 20 countries and an estradiol transdermal patch for hormone replacement therapy. “

NASDAQ ATRS traded down $0.12 on Tuesday, hitting $3.75. 712,819 shares of the company were exchanged, compared to its average volume of 1,173,943. The company’s 50 day moving average price is $4.08 and its 200-day moving average price is $3.86. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.47 and a quick ratio of 2.08. The firm has a market capitalization of $632.99 million, a P/E ratio of 62.51 and a beta of 1.44. Antares Pharma has a twelve month low of $2.39 and a twelve month high of $5.07.

Antares Pharma (NASDAQ:ATRS) last posted its quarterly earnings data on Monday, March 1st. The specialty pharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.04 by ($0.01). The company had revenue of $44.13 million for the quarter, compared to analyst estimates of $40.87 million. Antares Pharma had a return on equity of 16.48% and a net margin of 6.64%. As a group, equities analysts expect that Antares Pharma will post 0.07 EPS for the current year.

In other Antares Pharma news, CEO Robert F. Apple sold 491,960 shares of Antares Pharma stock in a transaction dated Thursday, February 18th. The stock was sold at an average price of $5.00, for a total transaction of $2,459,800.00. Following the transaction, the chief executive officer now owns 2,563,033 shares of the company’s stock, valued at approximately $12,815,165. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Robert F. Apple sold 33,574 shares of Antares Pharma stock in a transaction dated Monday, February 8th. The shares were sold at an average price of $4.75, for a total value of $159,476.50. Following the transaction, the chief executive officer now directly owns 2,328,729 shares in the company, valued at approximately $11,061,462.75. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 693,133 shares of company stock worth $3,398,068. Corporate insiders own 5.90% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in ATRS. Banque Cantonale Vaudoise purchased a new position in Antares Pharma during the 4th quarter valued at about $40,000. Truist Financial Corp bought a new stake in shares of Antares Pharma in the 4th quarter valued at approximately $48,000. Jane Street Group LLC bought a new stake in shares of Antares Pharma in the 4th quarter valued at approximately $52,000. Kestra Advisory Services LLC bought a new stake in shares of Antares Pharma in the 4th quarter valued at approximately $57,000. Finally, Teacher Retirement System of Texas bought a new stake in shares of Antares Pharma in the 4th quarter valued at approximately $57,000. 39.92% of the stock is currently owned by institutional investors.

Antares Pharma Company Profile

Antares Pharma, Inc, a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address unmet needs in targeted therapeutic areas. It develops, manufactures, and commercialize novel therapeutic products using its drug delivery systems.

Featured Article: What is the Difference Between Common Shares and Convertible Shares?

Get a free copy of the Zacks research report on Antares Pharma (ATRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.